Iovance Biotherapeutics, Inc.
HealthcareNASDAQ:IOVA · NASDAQ Global Market
+$0.12 today
Vol 10.92M · Avg 14.56M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$285.6M of revenue converted into -$353.9M of net income for the selected period. Gross margin is 104.5% and net margin is -128.8%, showing how much revenue survives after costs and taxes. EPS is $-0.92, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $263.5M +60.6% | $164.1M +13699.0% | $1.2M | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $7.3M -94.1% | $124.0M +1052.9% | $10.8M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $256.2M +539.3% | $40.1M +518.9% | -$9.6M | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 97.2% +72.8pp | 24.4% +829.0pp | -804.5% | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $300.3M +6.4% | $282.3M -17.9% | $344.1M +16.7% | $294.8M +13.8% | $259.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $152.3M -0.5% | $153.0M +43.1% | $106.9M +2.7% | $104.1M +24.4% | $83.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $659.6M +51.5% | $435.4M -3.5% | $451.0M +13.1% | $398.9M +16.4% | $342.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $35.9M -17.6% | $43.6M +31.6% | $33.1M +56.7% | $21.1M +51.2% | $14.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$357.1M -7.8% | -$331.4M +20.0% | -$414.4M -11.5% | -$371.8M -13.3% | -$328.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -135.5% +66.5pp | -202.0% +34649.9pp | -34851.9% | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$403.4M -2.0% | -$395.3M +14.2% | -$460.6M -15.5% | -$398.9M -16.4% | -$342.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -153.1% +87.8pp | -240.9% +38494.1pp | -38735.0% | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $20.3M +55.4% | $13.0M +337.0% | $3.0M +561.9% | $451.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 -100.0% | $3.0M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $10.3M -49.2% | $20.3M +55.4% | $13.0M +337.0% | $3.0M +561.9% | $451.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$393.0M -4.8% | -$375.0M +16.2% | -$447.5M -13.0% | -$395.9M -15.7% | -$342.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -149.2% +79.4pp | -228.6% +37409.5pp | -37638.0% | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$2.1M +26.8% | -$2.8M +18.7% | -$3.5M | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$391.0M -5.1% | -$372.2M +16.2% | -$444.0M -12.2% | -$395.9M -15.7% | -$342.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -148.4% +78.5pp | -226.8% +37118.6pp | -37345.4% | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +14.8% | -$1 +32.3% | -$2 +24.1% | -$2 -11.7% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +14.8% | -$1 +32.3% | -$2 +24.1% | -$2 -11.7% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $357.3M +23.3% | $289.9M +23.3% | $235.1M +47.6% | $159.3M +3.8% | $153.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $357.3M +23.3% | $289.9M +23.3% | $235.1M +47.6% | $159.3M +3.8% | $153.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IOVA generate?
Iovance Biotherapeutics, Inc. (IOVA) reported $263.50M of revenue in fiscal 2025.
Is IOVA profitable?
Iovance Biotherapeutics, Inc. (IOVA) reported -$390,978,000.00 of net income, with a net margin of -148.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.